Gemcitabine + Carbplatin + Paclitaxel→ Paclitaxel
Gemcitabine (Gemzar) 1000 mg/m2 iv d1, 8
Carbplatin (Paraplatin) AUC 5 iv d1
Paclitaxel (Taxol) 200 mg/m2 iv d1
Q3w x 4 cycles
Followed by
Paclitaxel (Taxol) 70 mg/m2 iv qw x 6 wks every 8 wks x 3 cycles

Greco FA et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research network study. J Clin Oncol 2002; 20:1651 (link to the article).

Carboplatin + Paclitaxel + Etoposide
Carboplatin (Paraplatin) AUC 6 iv d1
Paclitaxel (Taxol) 200 mg/m2 iv d1
Etoposide (VP-16) 50 mg alternating with 100 mg po d1-10
Q3w

Hainsworth JD et al. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin and extended-schedule etoposide. J Clin Oncol 1997; 15:2385 (link to the article).

Cisplatin + Etoposide + Bleomycin
Cisplatin (CDDP) 20 mg/m2/d iv d1-5
Etoposide (VP-16) 100 mg/m2/d iv d1-5
Bleomycin 30 U iv d1, 8 and 15
Q3w

Hainsworth JD et al. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly-differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992; 10:912 (link to article).

Bevacizumab + Erlotinib
Bevacizumab (Avastin) 10 mg/kg iv over 30-90 min q2w
Erlotinib (Tarceva) 150 mg po qd

Hainsworth JD et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: The Minnie Pearl Cancer Research Network. J Clin Oncol 2007; 25:1747 (link to the article).